Successful candidates will have the opportunity to initiate and conduct high-quality research within ProCURE (Program Against Cancer Therapeutic Resistance) at the Catalan Institute of Oncology: Dr. Pujana's group. Successful candidates will join a newly created translational research program focused on finding novel, advanced and personalized therapeutic strategies against cancer resistance. ProCURE involves strong clinical interactions and multidisciplinary approaches. The program offers a stimulating research atmosphere and an environment in which collaboration and exchange of ideas and techniques is actively encouraged with a strong commitment to translational research, which overall provides a lively and stimulating environment for young talents.
Dr. Pujana leads the Breast Cancer and Systems Biology research lab at the Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL) and, complementarily, leads a newly created ICO Research Program Against Cancer Therapeutic Resistance (ProCURE). This program consists of nine research groups with more than 700 peer-review publications. The overall aim of the research group is to better understand breast cancer development, the emergence of subtypes, and their therapeutic response/resistance. Particularly, the group’s research is focused on triple-negative and BRCA1-mutated (germline) breast cancer, which is in accordance to the current proposal. The group works on deciphering the molecular mechanisms that are perturbed at the germline level (by common genetic variation and rare mutations) influencing breast cancer risk, again particularly in BRCA1 mutation carriers (i.e. genetic modifiers of BRCA1 mutations penetrance). As such, the group is member of the international Consortium of Investigators of BRCA1/2 Modifiers (CIMBA), which also complements the proposed study.